
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is well-poised for success due to its diverse pipeline, strong intellectual property protection, and impressive clinical results for its lead gene therapy candidates. The company's recent data on AMT-191 for Fabry disease demonstrates durable, dose-dependent enzymatic production, positioning it as a potential one-time treatment for this rare genetic disorder. Additionally, the company's partnership with Bristol Myers Squibb for cardiovascular diseases further strengthens its platform and potential for future growth. With a focus on addressing unmet medical needs and a strong balance sheet, uniQure is positioned for long-term success and remains a top pick for investors in the gene therapy space.
Bears say
uniQure is a gene therapy company that has a limited pipeline with its lead candidate, AMT-130, facing potential delays with the FDA requiring a traditional sham-controlled trial for Huntington's disease. In addition, the company heavily relies on the success of AMT-130, and any setbacks or failures could adversely affect their business. Financial risks are also apparent, as the company has no revenue-generating products and is dependent on external funding for its development and commercialization efforts. The recent departure of the FDA's CBER director, known for supporting flexibility in approvals for rare diseases, adds further uncertainty for uniQure's future.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares